In short
Clinical trials investigating Alogliptin are studying how it performs in people with type 2 diabetes. These trials focus on treatment effects in adult participants and measure outcomes such as change in HbA1c, a blood test that shows average blood sugar over time.
Key points
- Alogliptin is listed in a clinical trial for adults with type 2 diabetes. The study is an interventional Phase 3 trial with 781 participants. The main outcome is change in HbA1c, which shows average blood sugar control over time. The source data show Alogliptin among several diabetes treatments used in the study context. The trial focuses on how treatment compares over time in people with type 2 diabetes.
Trial overview
The source data include one clinical trial that lists Alogliptin in the treatment set for adults with type 2 diabetes. The study is identified as NCT05433584 and is titled “A Study of Tirzepatide Compared with Intensified Conventional Care in Adult Participants with Type 2 Diabetes (SURPASS-EARLY).”
The trial status is Authorised, and the study type is Interventional, which means researchers are assigning treatments and measuring the results.
Who can participate
The target population in the trial is adult participants with type 2 diabetes. The source does not provide more detailed entry rules, such as exact age limits, lab values, or other health conditions.
- Adults: people who are old enough to join an adult study group.
- Type 2 diabetes: the condition being studied in this trial.
Study design and phase
The trial is in Phase 3, which is a later stage of clinical research. Phase 3 studies usually look at how well a treatment works in a larger group of people and continue to collect important safety and effectiveness information.
The enrollment is listed as 781, meaning 781 participants are included or planned for the study.
What is being measured
The primary outcome is change from baseline in Hemoglobin A1c (HbA1c). HbA1c is a blood test that shows average blood sugar over about 2 to 3 months. “Baseline” means the starting measurement before treatment begins.
The brief summary states that the study aims to show that tirzepatide is non-inferior to intensified conventional care for HbA1c change from baseline to Week 104. Non-inferior means the new treatment is not worse than the comparison treatment by more than a set amount.
Trial context and treatments listed
The intervention list in the source includes many diabetes medicines, including Alogliptin, along with other listed treatments such as sitagliptin, linagliptin, semaglutide, tirzepatide, dulaglutide, exenatide, liraglutide, lixisenatide, saxagliptin, vildagliptin, pioglitazone, metformin, and metformin with sulfonamides.
Some entries in the intervention list are shown as “-” with a dose and route, which likely reflects comparator or placeholder treatment entries in the source record, but the source does not explain them further.
For patients reading the trial record, the most important point is that Alogliptin appears in a study focused on diabetes treatment comparison and blood sugar control, not as a standalone drug monograph.
Patient-friendly terms
Interventional study means researchers give a treatment and then watch what happens. Primary outcome means the main result the study is built to measure. Week 104 means the study looks at results after 104 weeks, or about 2 years.
Intensified conventional care means standard treatment that is adjusted more closely or more strongly to improve diabetes control. This helps researchers compare how the study treatment performs against usual care that has been stepped up.